Inflectra
Infliximab-dyyb, the active ingredient in INFLECTRA, is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions) specific for human tumor necrosis factor-alpha (TNFα). It has a molecular weight of approximately 149.1 kilodaltons. Infliximab-dyyb is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that includes measures to inactivate and remove viruses.
Inflectra Info
INFLECTRA for injection is supplied as a sterile, white, lyophilized powder for intravenous infusion. Following reconstitution with 10 mL of Sterile Water for Injection, USP, the resulting pH is approximately 7.2. Each single-use vial contains 100 mg infliximab-dyyb, 500 mg sucrose, 0.5 mg polysorbate 80, 2.2 mg sodium dihydrogen phosphate monohydrate, and 6.1 mg di-Sodium hydrogen phosphate dihydrate.
Inflectra Side Effects
The most common side effects include:
- upper respiratory infections
- sinus infections
- runny or stuffy nose
- sore throat
- cough
- bronchitis
- infusion-related reactions
- headache
- abdominal pain
- nausea
- diarrhea
- indigestion
- rash
- itching
- fatigue
- pain
- fever
- oral thrush
- joint pain
- urinary tract infection, and
- high blood pressure (hypertension)
Patient Assistance Programs
There are several programs patients can sign up for that will assist in treatment costs:
Resources
To learn more about this treatment, browse the resources below.
Ready to get started?
Contact us to chat with one of our helpful scheduling specialists!